FindTrial
Sign In

T-cell activation enhances anti-HER2-mediated NK cell viability and antibody-dependent cellular cytotoxicity in gastric cancer

T-cell activation enhances anti-HER2-mediated NK cell viability and antibody-dependent cellular cytotoxicity in gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082487
Enrollment
Unknown
Registered
2024-03-29
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

none:none

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with HER2(+) gastric cancer by gastroscopic biopsy and have received Herceptin-related treatment; (2) TNM is staged T2-T4 (3) Age 18-79 years old; (4) Surgical pathological diagnosis from January 1, 2017 to December 31, 2022;

Exclusion criteria

Exclusion criteria: (1) Presence of other primary malignant tumors, (2) failure of vital organs, (3) pregnant or lactating women, (4) severe mental illness;

Design outcomes

Primary

MeasureTime frame
major pathological response;—

Countries

china

Contacts

Public ContactWang Xuefei

Zhongshan Hospital, Fudan University

wang.xuefei@zs-hospital.sh.cn+86 139 1727 0428

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026